US FDA Appoints Another Orphan Products Development Office Head Amid Growth Expectations
Janet Maynard will become acting Office of Orphan Products Development director at the end of October, the fourth head of the office in the last 10 months; staff is expected to grow and may begin to provide development advice.
You may also be interested in...
Sandra Retzky worked at AstraZeneca and in Delaware's Medicaid fraud unit before joining the US FDA in 2016.
OOPD’s deputy director has been named the acting head of the office responsible for orphan and rare pediatric disease designations.
Patient experience will be incorporated into agency orphan grant reviews, and outside rare disease experts will help make decisions.